Gorka San JosÃ©

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/420341/publications.pdf

Version: 2024-02-01

		159358	253896
46	3,190	30	43
papers	citations	h-index	g-index

47	47	47	4306
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oxidative Stress in Arterial Hypertension. Hypertension, 2001, 38, 1395-1399.	1.3	380
2	Vascular NADH/NADPH Oxidase Is Involved in Enhanced Superoxide Production in Spontaneously Hypertensive Rats. Hypertension, 2000, 35, 1055-1061.	1.3	339
3	Circulating Biomarkers of Myocardial Fibrosis. Journal of the American College of Cardiology, 2015, 65, 2449-2456.	1.2	196
4	Oxidative stress and vascular remodelling. Experimental Physiology, 2005, 90, 457-462.	0.9	129
5	Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nature Reviews Cardiology, 2021, 18, 479-498.	6.1	128
6	Myocardial Collagen Cross-Linking IsÂAssociated With Heart Failure Hospitalization in Patients With Hypertensive Heart Failure. Journal of the American College of Cardiology, 2016, 67, 251-260.	1.2	127
7	Myocardial Remodeling in Hypertension. Hypertension, 2018, 72, 549-558.	1.3	123
8	Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome. Diabetes, 2006, 55, 209-215.	0.3	121
9	Vascular oxidant stress: Molecular mechanisms and pathophysiological implications. Journal of Physiology and Biochemistry, 2000, 56, 57-64.	1.3	101
10	Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. Journal of Hypertension, 2004, 22, 2169-2175.	0.3	92
11	NADPH oxidase CYBA polymorphisms, oxidative stress and cardiovascular diseases. Clinical Science, 2008, 114, 173-182.	1.8	90
12	Functional Effect of the p22 phox â^'930 A/G Polymorphism on p22 phox Expression and NADPH Oxidase Activity in Hypertension. Hypertension, 2004, 44, 163-169.	1.3	89
13	Preliminary characterisation of the promoter of the human p22phox gene: identification of a new polymorphism associated with hypertension. FEBS Letters, 2003, 542, 27-31.	1.3	86
14	NADPH Oxidase-Mediated Oxidative Stress: Genetic Studies of thep22phoxGene in Hypertension. Antioxidants and Redox Signaling, 2005, 7, 1327-1336.	2.5	86
15	The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. Journal of Hypertension, 2006, 24, 1299-1306.	0.3	83
16	Phagocytic NADPH Oxidase-Dependent Superoxide Production Stimulates Matrix Metalloproteinase-9. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 587-593.	1.1	82
17	microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-Î²1 up-regulation. Clinical Science, 2014, 126, 497-506.	1.8	80
18	A 28-kDa Splice Variant of NADPH Oxidase-4 Is Nuclear-Localized and Involved in Redox Signaling in Vascular Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, e104-12.	1.1	71

#	Article	IF	Citations
19	Oxidative Stress, Endothelial Dysfunction and Cerebrovascular Disease. Cerebrovascular Diseases, 2007, 24, 24-29.	0.8	65
20	NADPH Oxidaseâ€“Dependent Superoxide Production Is Associated With Carotid Intima-Media Thickness in Subjects Free of Clinical Atherosclerotic Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1452-1457.	1.1	62
21	Polymorphisms and Promoter Overactivity of the p22phoxGene in Vascular Smooth Muscle Cells From Spontaneously Hypertensive Rats. Circulation Research, 2001, 88, 217-222.	2.0	61
22	Phenotyping of myocardial fibrosis in hypertensive patients with heart failure. Influence on clinical outcome. Journal of Hypertension, 2017, 35, 853-861.	0.3	58
23	The complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linking. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 1421-1432.	1.9	50
24	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation, 2020, 141, 751-767.	1.6	48
25	Is the balance between nitric oxide and superoxide altered in spontaneously hypertensive rats with endothelial dysfunction?. Nephrology Dialysis Transplantation, 2001, 16, 2-5.	0.4	46
26	Increased phagocytic nicotinamide adenine dinucleotide phosphate oxidaseâ€“dependent superoxide production in patients with early chronic kidney disease. Kidney International, 2005, 68, S71-S75.	2.6	45
27	HIF-1-mediated up-regulation of cardiotrophin-1 is involved in the survival response of cardiomyocytes to hypoxia. Cardiovascular Research, 2011, 92, 247-255.	1.8	42
28	Insulin-induced NADPH oxidase activation promotes proliferation and matrix metalloproteinase activation in monocytes/macrophages. Free Radical Biology and Medicine, 2009, 46, 1058-1067.	1.3	40
29	MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Scientific Reports, 2017, 7, 40696.	1.6	39
30	A novel CYBA variant, the â€“675A/T polymorphism, is associated with essential hypertension. Journal of Hypertension, 2007, 25, 1620-1626.	0.3	34
31	Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients. Journal of Hypertension, 2016, 34, 130-138.	0.3	30
32	A Synthetic Peptide from Transforming Growth Factor-Î²₁Type III Receptor Inhibits NADPH Oxidase and Prevents Oxidative Stress in the Kidney of Spontaneously Hypertensive Rats. Antioxidants and Redox Signaling, 2013, 19, 1607-1618.	2.5	21
33	Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Scientific Reports, 2017, 7, 41865.	1.6	21
34	The Hypertensive Myocardium. Medical Clinics of North America, 2017, 101, 43-52.	1.1	21
35	Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia, 2020, 40, 223-236.	0.2	21
36	Increased phagocytic NADPH oxidase activity associates with coronary artery calcification in asymptomatic men. Free Radical Research, 2017, 51, 389-396.	1.5	18

#	Article	IF	Citations
37	Association of Phagocytic NADPH Oxidase Activity With Hypertensive Heart Disease. Hypertension, 2014, 63, 468-474.	1.3	16
38	Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis. Clinical Science, 2013, 125, 291-300.	1.8	14
39	Insulin resistance determines phagocytic nicotinamide adenine dinucleotide phosphate oxidase overactivation in metabolic syndrome patients. Journal of Hypertension, 2009, 27, 1420-1430.	0.3	13
40	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2009, 116, 233-240.	1.8	8
41	Reprint of â€œThe complex dynamics of myocardial interstitial fibrosis in heart failure. Focus on collagen cross-linkingâ€• Biochimica Et Biophysica Acta - Molecular Cell Research, 2020, 1867, 118521.	1.9	7
42	The A640G CYBA polymorphism associates with subclinical atherosclerosis in diabetes. Frontiers in Bioscience - Elite, 2011, E3, 1467-1474.	0.9	5
43	The renal immune-inflammatory component of arterial hypertension: emerging therapeutic strategies. Cardiovascular Research, 2019, 115, 696-698.	1.8	2
44	The angiotensin-converting enzyme insertion/deletion polymorphism is associated with phagocytic NADPH oxidase-dependent superoxide generation: potential implication in hypertension. Clinical Science, 2010, 119, 185-185.	1.8	0
45	Corrigendum to â€œPreliminary characterisation of the promoter of the human p22phoxgene: Identification of a new polymorphism associated with hypertensionâ€•[FEBS Lett. 542 (2003) 27-31]. FEBS Letters, 2010, 584, 4709-4709.	1.3	0
46	Contrasting Regulation of NOX4 versus NOX2 in Patients with Aortic Stenosis. Free Radical Biology and Medicine, 2011, 51, S46.	1.3	0